Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Julie Hambleton Insider Profile
4 Followers
Julie Hambleton, EVP & Chief Medical Officer at Five Prime Therapeutics, holds 4.09K shares in Springworks Therapeutics (Ticker: SWTX), holds 2.00K shares in IGM Biosciences (Ticker: IGMS), holds 6.00K shares in Erasca (Ticker: ERAS).
Julie Hambleton Five Prime Therapeutics (FPRX)EVP & Chief Medical Officer
Five Prime Therapeutics (FPRX)
EVP & Chief Medical Officer
Ranked #16,136 out of 97,997 Corporate Insiders
Profitable Transactions
2 out of 5 Profitable Transactions
Average Return
+21.90%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Julie Hambleton holds in companies
Most Profitable Insider Trade
The most profitable trade made by Julie Hambleton
Julie Hambleton's Trading History
Five Prime Therapeutics
Nov 13, 2015
―
Informative Sell
800.24K
$3.29M
IGM Biosciences
Aug 11, 2021
Director
Uninformative Sell
80.00K
$23.40K
Springworks Therapeutics
Jun 05, 2024
Director
Uninformative Sell
186.03K
$171.62K
Erasca
Jul 20, 2021
Director
Informative Buy
96.00K
$19.38K
List of latest transactions for each holding click on a transaction to see Julie Hambleton's performance on stock
You May Also Like
Julie Hambleton insider profile FAQ
What is the percentage of profitable transactions made by Julie Hambleton?
The percentage of profitable transactions made by Julie Hambleton is 40%.
What is the average return per transaction made by Julie Hambleton?
The average return per transaction made by Julie Hambleton is 21.90%.
What stocks does Julie Hambleton hold?
Julie Hambleton holds: FPRX, IGMS, SWTX, ERAS stocks.
What was Julie Hambleton’s latest transaction?
Julie Hambleton latest transaction was an Uninformative Sell of $186.03K.
What was Julie Hambleton's most profitable transaction?
Julie Hambleton’s most profitable transaction was an Informative Buy of IGMS stock on September 20, 2019. The return on the trade was 291.90%.
What is Julie Hambleton's role in Five Prime Therapeutics?
Julie Hambleton's role in Five Prime Therapeutics is EVP & Chief Medical Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.